These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11571515)

  • 21. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register.
    Isbister J; Phillips L; Dunkley S; Jankelowitz G; McNeil J; Cameron P
    Intern Med J; 2008 Mar; 38(3):156-65. PubMed ID: 17916172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant factor VIIa: unregulated continuous use in patients with bleeding and coagulopathy does not alter mortality and outcome.
    Ganguly S; Spengel K; Tilzer LL; O'neal B; Simpson SQ
    Clin Lab Haematol; 2006 Oct; 28(5):309-12. PubMed ID: 16999720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors.
    O'Connell N; Mc Mahon C; Smith J; Khair K; Hann I; Liesner R; Smith OP
    Br J Haematol; 2002 Mar; 116(3):632-5. PubMed ID: 11849223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilization of recombinant activated factor VII in southern Ontario in 85 patients with and without haemophilia.
    Webert KE; Arnold DM; Carruthers J; Molnar L; Almonte T; Decker K; Seroski W; Reed J; Chan AK; Pai M; Walker IR
    Haemophilia; 2007 Sep; 13(5):518-26. PubMed ID: 17880438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa?
    Poon MC
    Curr Hematol Rep; 2003 Mar; 2(2):139-47. PubMed ID: 12901145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma.
    Martinowitz U; Kenet G; Lubetski A; Luboshitz J; Segal E
    Can J Anaesth; 2002 Dec; 49(10):S15-20. PubMed ID: 12546003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antidotes to haemorrhage: recombinant factor VIIa.
    Kessler CM
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):183-97. PubMed ID: 15171966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel hemostatic agent: the potential role of recombinant activated factor VII (rFVIIa) in anesthetic practice.
    Murkin JM
    Can J Anaesth; 2002 Dec; 49(10):S21-6. PubMed ID: 12546007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "Off-license" use of recombinant activated factor VII.
    Ghorashian S; Hunt BJ
    Blood Rev; 2004 Dec; 18(4):245-59. PubMed ID: 15501553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Congenital factor VII deficiency: therapy with recombinant activated factor VII -- a critical appraisal.
    Mariani G; Konkle BA; Ingerslev J
    Haemophilia; 2006 Jan; 12(1):19-27. PubMed ID: 16409171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Off-label use of recombinant activated factor VII in surgical and non-surgical patients at 16 Canadian hospitals from 2007 to 2010 (Canadian Registry Report).
    Karkouti K; Arellano R; Aye T; Dupuis JY; Kent B; Lee TW; Lin Y; Ralley F; MacAdams C; Mazer CD; Muirhead B; Rheault MR; Rochon A; Syed S; Waters T; Wong B
    Can J Anaesth; 2014 Aug; 61(8):727-35. PubMed ID: 24890696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.
    Morfini M; Auerswald G; Kobelt RA; Rivolta GF; Rodriguez-Martorell J; Scaraggi FA; Altisent C; Blatny J; Borel-Derlon A; Rossi V
    Haemophilia; 2007 Sep; 13(5):502-7. PubMed ID: 17880436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII.
    Filsoufi F; Castillo JG; Rahmanian PB; Scurlock C; Fischer G; Adams DH
    Ann Thorac Surg; 2006 Nov; 82(5):1779-83. PubMed ID: 17062247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes.
    MacLaren R; Weber LA; Brake H; Gardner MA; Tanzi M
    Transfusion; 2005 Sep; 45(9):1434-42. PubMed ID: 16131375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors.
    Schneiderman J; Nugent DJ; Young G
    Haemophilia; 2004 Jul; 10(4):347-51. PubMed ID: 15230948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful management of intra-abdominal hemorrhage in the presence of severe alcoholic liver disease with activated recombinant factor VII (rFVIIa; NovoSeven): a case report and review of the literature on approved and off-label use of rFVIIa.
    Agarwal N; Spahr JE; Rodgers GM
    Blood Coagul Fibrinolysis; 2007 Mar; 18(2):205-7. PubMed ID: 17287641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant factor VIIa (NovoSeven) as a hemostatic agent.
    Hedner U
    Dis Mon; 2003 Jan; 49(1):39-48. PubMed ID: 12525827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant-activated coagulation factor VIIa (NovoSeven): current development.
    Weiskopf RB
    Vox Sang; 2007 May; 92(4):281-8. PubMed ID: 17456151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency.
    Tcheng WY; Donkin J; Konzal S; Wong WY
    Haemophilia; 2004 May; 10(3):295-8. PubMed ID: 15086331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage.
    Allen GA; Hoffman M; Roberts HR; Monroe DM
    Can J Anaesth; 2002 Dec; 49(10):S7-14. PubMed ID: 12546000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.